share_log
Reuters ·  Apr 26 06:59
Chmp Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (Nivolumab) in Combination With Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment